ASH 2022 Conference Coverage
Playback speed
10 seconds
ASH 2022 Results of the ASC4MORE Study: Asciminib Add-On to Imatinib, Continued Imatinib, or Switch to Nilotinib in Pts With CML-CP Not Achieving Deep Molecular Responses With ≥1 Year of Imatinib
By
ASH 2022 Conference Coverage
FEATURING
Giuseppe Saglio
By
ASH 2022 Conference Coverage
FEATURING
Giuseppe Saglio
82 views
January 11, 2023
Login to view comments.
Click here to Login
Leukemia